Zhonghua Yi Xue Za Zhi. 2024 Apr 16;104(15):1258-1279. doi: 10.3760/cma.j.cn112137-20240124-00179.
Pertussis re-emergence is a global public health concern. The reported incidence of pertussis in China from 2018 to 2022 was comparable to that in the late 1980s. In fact, the incidence of pertussis is still significantly underestimated in China, owing to a lack of comprehensive active pertussis surveillance, missed diagnosis of atypical pertussis cases, and the fact that many medical institutions do not perform pertussis laboratory diagnosis. Meanwhile, China is also faced with the clinical issue that Bordetella pertussis is highly resistant to first-line macrolide treatment. To better guide and standardize the clinical diagnosis, treatment, monitoring, prevention and control of pertussis cases in China, a multidisciplinary guideline development group comprised of experts in infectious diseases, epidemiology, immunization planning and guideline methodology proposed 12 clinical issues related to the diagnosis, treatment and prevention, especially vaccine immunization strategies from a practical perspective. Through research question construction, evidence retrieval and synthesis, evidence appraisal and evidence-to-decision discussion, recommendations and implementation suggestions were formulated to provide references for clinical physicians engaged in the diagnosis and management of pertussis, microbiological laboratory professionals, hospital infection control professionals, and public health professionals involved in infectious disease prevention, control and immunization planning.
百日咳的再度流行是一个全球公共卫生问题。2018年至2022年中国报告的百日咳发病率与20世纪80年代末相当。事实上，由于缺乏全面的百日咳主动监测、非典型百日咳病例的漏诊以及许多医疗机构未开展百日咳实验室诊断，中国百日咳的发病率仍被严重低估。同时，中国还面临着百日咳博德特菌对一线大环内酯类治疗高度耐药的临床问题。为更好地指导和规范中国百日咳病例的临床诊断、治疗、监测、预防和控制，一个由传染病、流行病学、免疫规划和指南方法学专家组成的多学科指南制定小组从实际角度提出了1２个与诊断、治疗和预防相关的临床问题，特别是疫苗免疫策略。通过构建研究问题、检索和综合证据、评估证据以及证据到决策的讨论，制定了建议和实施建议，为从事百日咳诊断和管理的临床医生、微生物实验室专业人员、医院感染控制专业人员以及参与传染病预防控制和免疫规划的公共卫生专业人员提供参考。
